• Samsung Ventures invests in Araris
• Proceeds will be used to support the continued development and advancement of Araris’ antibody-drug conjugate (ADC) candidates

AU ZH, Switzerland, April 11, 2023 (GLOBE NEWSWIRE) — Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC) linker technology , announced today that Samsung Venture Investment Corporation (“Samsung Ventures”), an investment firm formed to advance the development of new technologies, has invested in the company in an independent transaction prior to its ongoing Series A financing .

The investment was made through the Samsung Life Science Fund – co-established by Samsung Biologics (KRX: 207940.KS) and Samsung C&T and managed by Samsung Ventures – reflecting Samsung’s commitment to further explore and grow various business opportunities in the biopharmaceuticals space .

Araris Biotech is a company pioneering a proprietary antibody-drug conjugate (ADC) linker technology where its linker platform allows attachment of payloads to commercially available antibodies without the need for antibody redesign or downsizing, resulting in highly homogeneous, stable, and effective ADC therapies in a cost- and time-efficient manner. It also has the potential to address challenges related to ADCs, including solubility and unstable binding issues.

The latest investment reflects Samsung’s commitment to continue expanding its pipeline. As a strategic investor, Samsung will work with Araris to evaluate, manufacture and develop assets using its proprietary ADC technology, in close collaboration with Samsung subsidiaries involved in the discovery and development and manufacturing of novel biologics.

“Araris has the potential to develop first-in-class ADC therapies and we see room for collaboration in the manufacturing and development of new drugs,” said John Rim, CEO of Samsung Biologics.

“We are pleased about this support from Samsung as well as about the…